Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DCCR Dose Titration and Withdrawal in Prader-Willi Syndrome
NCT02034071Phase 2Completed
- Sponsor
- Essentialis, Inc.
- Start
- Apr 2014
- Primary completion
- May 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Prader-Willi syndrome (PWS) comparing DCCR Maintenance with Placebo Withdrawal (2 arms). Primary endpoints: Hyperphagia using hyperphagia questionnaire and Resting energy expenditure. Started Apr 2014; status: completed.
02
Drugs
diazoxide
03
Conditions
Prader-Willi syndrome (PWS)
Beyond the preview
Go deeper on NCT02034071.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02034071.